Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Epalrestat is a potent and selective aldose reductase inhibitor (ARI) primarily developed for the management of diabetic complications, particularly diabetic peripheral neuropathy. Its molecular formula is C18H16Cl2N4O2S, with a corresponding CAS registry number of 97330-53-3. Structurally, Epalrestat features a distinctive quinazoline core substituted with chlorine atoms and a thiazole ring, which facilitates high-affinity binding to the active site of the aldose reductase enzyme. This specific enzymatic inhibition disrupts the polyol pathway, a metabolic route that becomes hyperactive under chronic hyperglycemic conditions. In this pathway, excess glucose is converted into sorbitol by aldose reductase, leading to intracellular osmotic stress, oxidative damage, and eventual nerve dysfunction. By blocking this conversion, Epalrestat effectively reduces sorbitol accumulation within tissues, thereby mitigating cellular injury and preserving nerve conduction velocity.
Clinically, Epalrestat has been widely utilized in Japan and other parts of Asia as a first-line therapy for early-stage diabetic neuropathy. It is indicated to improve symptoms such as numbness, pain, and thermal sensitivity in patients with type 1 or type 2 diabetes. Unlike some older ARIs, Epalrestat demonstrates a favorable safety profile with minimal off-target effects when administered at therapeutic doses. The drug is typically administered orally, usually three times daily, allowing for convenient patient compliance. While it does not cure diabetes itself, it plays a crucial role in slowing the progression of microvascular complications associated with long-term glycemic control issues. Extensive pharmacological studies have confirmed its ability to restore normal nerve function and reduce oxidative stress markers. As research continues, Epalrestat remains a significant benchmark in the development of novel agents targeting the polyol pathway, offering hope for improved quality of life for millions of diabetic patients worldwide suffering from neuropathic disorders.